Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087984 · ClinicalTrials.gov registry record · Phase 1
RNA-Loaded Dendritic Cell Cancer Vaccine
A Phase 1 study, sponsored by Argos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00087984 is a Phase 1 study that has completed, run by Argos Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT00087984, a Phase 1 study, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.
Interventions
- BIOLOGICAL MB-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087984
The ClinicalTrials.gov registry entry for NCT00087984 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Argos Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MB-002 is the first listed.
NCT00087984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087984 about?
NCT00087984 is a clinical study titled "RNA-Loaded Dendritic Cell Cancer Vaccine". The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.
What is the current status of trial NCT00087984?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2004-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00087984?
The interventions under investigation include: MB-002 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00087984?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.